Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
life sciences
national blog main
new york blog main
new york top stories
8
×
national top stories
biotech
clinical trials
fda
new york
san francisco blog main
san francisco top stories
amgen
boston
inclisiran
regeneron pharmaceuticals
sanofi
startups
alnylam pharmaceuticals
biogen
blackstone group
cancer
cholesterol
david goldstein
deals
depression
drug discovery
epilepsy
essential tremor
investing
ipo
kiran reddy
major depressive disorder
novartis
pcsk9
pcsk9 inhibitors
perimenopausal depression
praluent
praxis precision medicines
What
medicines
8
×
new
cholesterol
drug
drugs
fda
medco
research
aims
ceo
developing
ipo
lowering
morning
praxis
precision
touting
twice
aces
acquire
activity
agreed
announced
approach
approvals
backed
based
big
billion
bio
biogen
biotech
biotechs
bringing
brings
called
cash
cause
central
clamped
Language
unset
8
×
Current search:
unset
×
" boston top stories "
×
" new york top stories "
×
medicines
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing